Effects of Chest Physiotherapy in Hyperventilation Syndrome

Hyperventilation Clinical Trial

— SHV  

Official title:

Effects of Chest Physiotherapy in Hyperventilation Syndrom : a Multicentric Observational Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05488301
• Other study ID #: CHPMorlaix
• Secondary ID: CEPRO 2021-028
• Status: Completed
• Start date: October 1, 2021
• Est. completion date: August 1, 2023

Study information

• Verified date: August 2023
• Source: Centre Hospitalier des Pays de Morlaix
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Hyperventilation syndrome induce dyspnea and altered quality of life. the aim of this study is to assess the impact of chest physiotherapy on hyperventilation syndrome' symptoms

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: August 1, 2023
• Est. primary completion date: August 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patients addressed for hyperventilation syndrome

• patient aged 18 years or over

• patient able to consent and having sign a consent form

Exclusion Criteria:

• respiratory disease (COPD, interstitial lung disease, bronchiectasis, cystic fibrosis, uncontrolled asthma)

• patient with an inability to complete questionaires

• refusal of participation

• patient under tutorship or curatorship

Related Conditions & MeSH terms

• Hyperventilation

Intervention

Other:
• chest physiotherapy
chest physiotherapy session including: nasal ventilation decrease of respiratory rate without increasement of Tidal volume abdomino-diaphragmatic ventilation

Locations

Country	Name	City	State
France	BEAUMONT	Morlaix

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier des Pays de Morlaix

Country where clinical trial is conducted

France, 

References & Publications (2)

Chenivesse C, Similowski T, Bautin N, Fournier C, Robin S, Wallaert B, Perez T. Severely impaired health-related quality of life in chronic hyperventilation patients: exploratory data. Respir Med. 2014 Mar;108(3):517-23. doi: 10.1016/j.rmed.2013.10.024. Epub 2013 Nov 7. — View Citation

Kiesel K, Burklow M, Garner MB, Hayden J, Hermann AJ, Kingshott E, McCullough G, Ricard R, Stubblefield G, Volz J, Waskiewicz D, Englert A. EXERCISE INTERVENTION FOR INDIVIDUALS WITH DYSFUNCTIONAL BREATHING: A MATCHED CONTROLLED TRIAL. Int J Sports Phys Ther. 2020 Feb;15(1):114-125. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change of Nijmegen score	Nijmegen score is measured at baseline and after 5 weeks. The Nijmegen questionnaire allows to assess hyperventilation symptoms. the minimum and maximum values are between 0 to 64, and higher scores mean a worse outcome.	5 weeks
Secondary	change of Nijmegen Score	Nijemegen score is measured at baseline and after 1 week. The Nijmegen questionnaire allows to assess hyperventilation symptoms the minimum and maximum values are between 0 to 64, and higher scores mean a worse outcome.	1 week
Secondary	change of Hospital Anxiety and Depression score (HAD)	Anxiety and depression scores are measured at baseline and after 5 weeks. the minimum and maximum values are between 0 to 21 for each item (Anxiety and Depression), and higher scores mean a worse outcome.	5 weeks
Secondary	change of Short Form-36 score (SF-36)	SF 36 score is measured at baseline and after 5 weeks. SF36 allows to assess quality of life.; the minimum and maximum values are between 0 to 100, and higher scores mean a better outcome.	5 weeks
Secondary	change of Dyspnea-12 score	Dyspnea-12 is measured at at baseline and after 5 weeks.; Dyspnea-12 questionnaire allows to assess sensorial and emotional component of dyspnea. The minimum and maximum values are between à to 36, and higher scores mean a worse outcome.	5 weeks